![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
Direxion Daily Semiconductor Bull 3x Shares ETF
SOXL
Direxion Daily Energy Bear 2X Shares
ERY
Direxion Daily Financial Bull 3X Shares ETF
FAS
4
SPDR S&P Homebuilders ETF
XHB
5
VanEck Semiconductor ETF
SMH
US Stock MarketDetailed Quotes
Aclaris Therapeutics (ACRS)
- 4.340
- -0.020-0.46%
Close Jun 16 16:00 ET
- 4.340
- 0.0000.00%
Post 17:26 ET
606.14MMarket Cap-7.75P/E (TTM)
4.430High4.245Low1.09MVolume4.370Open4.360Prev Close4.69MTurnover0.96%Turnover RatioLossP/E (Static)139.66MShares5.15052wk High4.22P/B491.01MFloat Cap1.34352wk Low--Dividend TTM113.14MShs Float33.880Historical High--Div Yield TTM4.24%Range %0.590Historical Low4.316Avg Price1Lot Size
ACRS Stock Chart
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
ACRS Orderflow
Unit: --
ACRS Orderflow Trend
IntradayDayWeekMonth
No Data
Aclaris Therapeutics (ACRS) News
Aclaris Stockholders Approve Directors, Pay and Auditor
This Piper Sandler Analyst Begins Coverage On A Bullish Note; Here Are Top 3 Initiations From Tuesday
New Analyst Forecast: $ACRS Given $13 Price Target
Aclaris Therapeutics Price Target Announced at $13.00/Share by LifeSci Capital
Aclaris Therapeutics Initiated at Outperform by LifeSci Capital
LifeSci Capital Initiates Aclaris Therapeutics(ACRS.US) With Buy Rating, Announces Target Price $13
Aclaris Therapeutics (ACRS) Stock Forum
$Aclaris Therapeutics (ACRS.US)$ will participate in two upcoming healthcare conferences in February 2026.
On Thursday February 12, 2026, at 2:30 PM EST, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY.
On Thursday February 26, 2026, at 8:40 AM EST, Aclaris' President and Chief Operating Officer H...
On Thursday February 12, 2026, at 2:30 PM EST, Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Guggenheim Emerging Outlook: Biotech Summit 2026 in New York, NY.
On Thursday February 26, 2026, at 8:40 AM EST, Aclaris' President and Chief Operating Officer H...
4
4
$Aclaris Therapeutics (ACRS.US)$ Reuters
1m
Aclaris Therapeutics’ Novel Itk/Jak3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (Aa)! Aclaris Therapeutics Inc - to Initiate Phase 2B Trial for ATI-2138 in First Half of 2026!
1m
Aclaris Therapeutics’ Novel Itk/Jak3 Inhibitor ATI-2138 Demonstrates Rapid and Sustained Hair Regrowth in Validated Murine Model of Alopecia Areata (Aa)! Aclaris Therapeutics Inc - to Initiate Phase 2B Trial for ATI-2138 in First Half of 2026!
1
$Aclaris Therapeutics (ACRS.US)$
climb baby climb
climb baby climb
Global Markets
$Dow Jones Industrial Average (.DJI.US)$: -1.76%,
$S&P 500 Index (.SPX.US)$: -2.06%,
$Nasdaq Composite Index (.IXIC.US)$: -2.39%
U.S. stocks tumbled on Tuesday as fresh trade tensions spooked investors after President Donald Trump threatened new tariffs on several European countries over the Greenland dispute. The Nasdaq slid 2.39%, the S&P 500 dropped 2.06%, and the Dow Jones Ind...
$Dow Jones Industrial Average (.DJI.US)$: -1.76%,
$S&P 500 Index (.SPX.US)$: -2.06%,
$Nasdaq Composite Index (.IXIC.US)$: -2.39%
U.S. stocks tumbled on Tuesday as fresh trade tensions spooked investors after President Donald Trump threatened new tariffs on several European countries over the Greenland dispute. The Nasdaq slid 2.39%, the S&P 500 dropped 2.06%, and the Dow Jones Ind...
+6
25
Read more
Market Insights
Hot Topics Hot Topics
Surf the ETF wave: Master the market with wisdom & ease!
As the financial landscape evolves, ETFs have emerged as a versatile tool for investors seeking to grow wealth, diversify portfolios, and st
102362254
Sep 4, 2024 16:25
Sharing my long-term ETF story
mr_cashcow
Sep 11, 2024 10:30
Low cost ETF is the way to go! September P/L challenge #6 (200words count entry)